Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Trading DecisionBuy
Generated at:2026-04-17 17:46:11
Analysis data includes current stock price ($927.03), target price framework (1-month: $990, 3-month: $1,095, 6-month: $1,310), financial metrics (2025 revenue: $65.18B, gross margin: 83.04%, Debt/Assets: 76.41%), technical indicators (support/resistance levels, MACD, Bollinger Bands), and market sentiment data (Morgan Stanley price target, social sentiment). Data sources include company financials, technical analysis, and market research reports.
Summary

Trading strategy overview: Eli Lilly and Company (LLY) receives a BUY recommendation with a 3-month target price of $1,095, representing an expected 18.1% increase from the current price of $927.03. A stop-loss price is set at $899 to manage downside risk. The confidence level in this decision is 0.75, supported by a fundamental catalyst but tempered by valuation concerns. The risk score is assessed at 0.65, reflecting high risk due to extreme valuation multiples and competitive pressures in the market.

Operation strategy
  • Entry between $917-$920 (MA support cluster) or on breakout above $963.50 with volume
  • Position sizing should be reduced due to high volatility (ATR $28 = 3.0% daily range)
  • Stop-loss set at $899 (below key chip support and recent swing low)
  • Time horizon aligns with 3-month primary target, coinciding with next earnings cycle and prescription trend updates

Core Support

Reasoning summary
  • Foundayo's Phase III cardiovascular outcomes data (ACHIEVE-4 trial) represents a fundamental inflection point, opening the massive Type 2 diabetes market
  • The data demonstrates cardiovascular safety and superior A1C/weight loss effects, essential for payer coverage
  • A 57% reduction in all-cause mortality provides compelling clinical differentiation
  • Foundayo now has validated blockbuster potential in both obesity AND diabetes markets
  • Technical indicators suggest selling exhaustion with price bouncing from $904 support
  • MACD histogram turned positive (+2.44), indicating decelerating bearish momentum
  • Explosive growth: 44.7% YoY revenue increase to $65.18B (2025) with exceptional profitability
  • Extreme valuation (Forward P/E of 91.43) and execution risk in scaling GLP-1 production are key risks
  • Market is re-pricing LLY based on expanded total addressable market and reduced regulatory overhang